OncLive On Air partners with Two Onc Docs to bring insights on primary data from the LAURA trial, which were presented at the 2024 ASCO Annual Meeting.
CHICAGO — Osimertinib following chemoradiotherapy drastically improved PFS compared with placebo in patients with advanced EGFR-mutant non-small cell lung cancer in a randomized phase 3 trial.Blinded independent review and study investigators separately determined a greater than 80% risk reduction for those treated with the osimertinib-based regimen, according to results presented at ASCO
Takeda Presents Updated Results for Mobocertinib quicknews-africa.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from quicknews-africa.net Daily Mail and Mail on Sunday newspapers.
Winship has received renewal of the prestigious Comprehensive Cancer Center designation from the National Cancer Institute, ensuring its continuing place in the top tier of cancer centers in the United States.